Skip to content
value.today

Genocea Biosciences, Inc.

Total raised
$153 M
4 rounds on record
Latest round
$76 M
Jul 2020
First round on record
Dec 2010
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Genocea Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2020$76 MNo. 4$50 to $250 million

Genocea Biosciences, Inc.: Raise no. 4, Jul 2020

Investors in this round

18 investors had bought by the notice of Aug 3, 2020: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Genocea Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$76 M of $80 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$4,790,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Diantha Duvall · Executive Officer
  • Girish Aakalu · Executive Officer
  • Jessica Flechtner · Executive Officer
  • Thomas Davis · Executive Officer
  • William Clark · Executive Officer
  • Ali Behbahani · Director
  • George Siber · Director
  • Gisela Schwab · Director
  • Howard Mayer · Director
  • Katrine Bosley · Director
  • Kenneth Bate · Director
  • Michael Higgins · Director
  • Ronald Cooper · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • STIFEL, NICOLAUS & COMPANY, INCORPORATED (CRD 793) · St. Louis, MissouriSold in all US states

Remarks in the notice

  • On the amounts: “TOTAL REMAINING TO BE SOLD REPRESENTS PRE-FUNDED WARRANTS AND WARRANTS TO PURCHASE SHARES OF COMMON STOCK; SUCH PRE-FUNDED WARRANT AND WARRANTS HAVE NOT YET BEEN EXERCISED.”

Signed by Diantha Duvall, Chief financial officer. Newest notice filed Aug 3, 2020. Read the notice at the SEC.

equity, optionsSEC
Feb 2019$12 MNo. 3$10 to $50 million

Genocea Biosciences, Inc.: Raise no. 3, Feb 2019

Investors in this round

9 investors had bought by the notice of Feb 27, 2019: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Genocea Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $15 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$750,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Derek Meisner · Executive Officer
  • Girish Aakalu · Executive Officer
  • Jessica Flechtner · Executive Officer
  • Michael Alfieri · Executive Officer
  • Narinder Singh · Executive Officer
  • Pamela Carroll · Executive Officer
  • Thomas Davis · Executive Officer
  • William Clark · Executive Officer
  • Ali Behbahani · Director
  • George Siber · Director
  • Howard Mayer · Director
  • Katrine Bosley · Director
  • Kenneth Bate · Director
  • Michael Higgins · Director
  • Ronald Cooper · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Remaining to be Sold represents pre-funded warrants and warrants to purchase shares of Common Stock; such pre-funded warrant and warrants have not yet been exercised.”

Signed by Derek Meisner, Senior Vice President and General Counsel. Newest notice filed Feb 27, 2019. Read the notice at the SEC.

equity, optionsSEC
Sep 2012$31 MNo. 2$10 to $50 million

Genocea Biosciences, Inc.: Raise no. 2, Sep 2012

Investors in this round

21 investors had bought by the notice of Jul 2, 2013: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Genocea Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$31 M of $31 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jessica Baker Flechtner · Executive Officer
  • Paul Baker Giannasca · Executive Officer
  • Ravi Baker Venkataramani · Executive Officer
  • Robert E. Farrell Jr. · Executive Officer
  • Seth Baker Hetherington · Executive Officer
  • William Baker Clark · Executive Officer, Director
  • Asish Xavier · Director
  • George Siber · Director
  • Kevin Bitterman · Director
  • Robert Paull · Director
  • Simeon George · Director
  • Stephen Hoffman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert E. Farrell Jr., Vice president of finance and administration. Newest notice filed Jul 2, 2013 (1 amendment). Read the notice at the SEC.

equitySEC
Dec 2010$35 MNo. 1$10 to $50 million

Genocea Biosciences, Inc.: Raise no. 1, Dec 2010

Investors in this round

16 investors had bought by the notice of Jan 3, 2011: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Genocea Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$35 M of $35 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dalton Einhorn · Executive Officer, Director
  • Jessica Baker Flechtner · Executive Officer
  • Paul Baker Giannasca · Executive Officer
  • Robert Farrell Jr. · Executive Officer
  • William Baker Clark · Executive Officer
  • George Siber · Director
  • Kevin Bitterman · Director
  • Robert Paull · Director
  • Simeon George · Director
  • Steve Hoffman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William Clark, Chief business officer. Newest notice filed Jan 3, 2011. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Genocea Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2020).

    SEC Form D · Aug 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Aug 2020

Products and services#

No products or services on record: its website does not allow automated readers.

Investors#

13 named in official filings. Open an investor to see everything it has backed.

Investors in Genocea Biosciences, Inc.
InvestorKindAmountRoundRoleSource
GSK PLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Johnson & Johnson Development Corp Et AlCompanynot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Lux Capital Management, LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Lux Venture Associates II, LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Lux Venture Partners II, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Lux Ventures II, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Lux Ventures II Sidecar II LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Lux Ventures II Sidecar LPVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Management Co. V, L.L.C.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners Entrepreneurs' Fund V, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners Special Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners V, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Genocea Biosciences, Inc.
NameRoleNamed in
Diantha DuvallExecutive officerAug 2020
Girish AakaluExecutive officerAug 2020
Jessica FlechtnerExecutive officerAug 2020
Thomas DavisExecutive officerAug 2020
William ClarkExecutive officerAug 2020
Derek MeisnerExecutive officerFeb 2019
Michael AlfieriExecutive officerFeb 2019
Narinder SinghExecutive officerFeb 2019
Pamela CarrollExecutive officerFeb 2019
Jessica Baker FlechtnerExecutive officerJul 2013
Paul Baker GiannascaExecutive officerJul 2013
Ravi Baker VenkataramaniExecutive officerJul 2013
Robert E. Farrell Jr.Executive officerJul 2013
Seth Baker HetheringtonExecutive officerJul 2013
William Baker ClarkExecutive officerJul 2013
Dalton EinhornExecutive officerJan 2011
Robert Farrell Jr.Executive officerJan 2011
Ali BehbahaniDirectorAug 2020
George SiberDirectorAug 2020
Gisela SchwabDirectorAug 2020
Howard MayerDirectorAug 2020
Katrine BosleyDirectorAug 2020
Kenneth BateDirectorAug 2020
Michael HigginsDirectorAug 2020
Ronald CooperDirectorAug 2020
Asish XavierDirectorJul 2013
Kevin BittermanDirectorJul 2013
Robert PaullDirectorJul 2013
Simeon GeorgeDirectorJul 2013
Stephen HoffmanDirectorJul 2013
William Baker ClarkDirectorJul 2013
Leon ChenDirectorOct 2012
Dalton EinhornDirectorJan 2011
Steve HoffmanDirectorJan 2011

About

Company in Cambridge, United States.